{"hands_on_practices": [{"introduction": "Therapeutic drug monitoring is foundational to the safe use of medications with a narrow therapeutic index, such as lithium. A core tenet of this practice is to measure drug concentrations only at steady state, the point at which drug administration and elimination rates are in equilibrium. This exercise [@problem_id:4730649] moves beyond rote memorization of the \"five half-lives\" rule, guiding you to derive this principle from first-order kinetics and apply it to a practical clinical task: scheduling a patient's first valid lithium level check.", "problem": "A 35-year-old patient with Bipolar I disorder is initiated on lithium carbonate using twice-daily dosing every $12$ hours (q$12$h). You are asked to schedule the earliest reliable time for the first serum lithium level that reflects near steady state for safety and efficacy monitoring, given lithium’s narrow therapeutic window and risks including renal and thyroid adverse effects. Assume the following foundational pharmacokinetic conditions, which are well established for lithium in adults with normal renal function: linear, first-order elimination; a one-compartment model at the level of accumulation to plateau; and measurement of a trough concentration just prior to a scheduled dose. Population pharmacokinetic data for this adult suggest an elimination half-life of $t_{1/2} = 21.3$ hours.\n\nStarting from the first-order elimination law and the definition of half-life, and using the clinical convention that “steady state” for monitoring can be operationalized as the time $t_{ss}$ at which the concentration has reached at least $1 - 2^{-5}$ of its asymptotic steady-state value, derive an expression for $t_{ss}$ in terms of $t_{1/2}$ and use it to compute the earliest scheduled trough time (in hours from the first dose) at or after $t_{ss}$ under the $12$-hour dosing interval. Round your final numerical answer to four significant figures and express it in hours. Do not provide intermediate times; report only the single earliest trough time that meets the near–steady-state criterion and the dosing schedule constraint.", "solution": "The problem asks for the earliest valid time to measure a trough serum lithium level, where \"valid\" implies the concentration is near steady state. The problem is well-posed and scientifically grounded in pharmacokinetic principles.\n\nThe analysis begins with the foundational principle of first-order elimination kinetics. For a drug following a one-compartment model with first-order elimination, the concentration $C(t)$ at time $t$ after drug administration ceases is described by the differential equation:\n$$\n\\frac{dC}{dt} = -k_e C\n$$\nwhere $k_e$ is the first-order elimination rate constant. The solution to this equation is:\n$$\nC(t) = C_0 \\exp(-k_e t)\n$$\nwhere $C_0$ is the concentration at $t=0$.\n\nThe elimination half-life, $t_{1/2}$, is defined as the time required for the concentration to decrease by half. Setting $C(t_{1/2}) = \\frac{1}{2} C_0$:\n$$\n\\frac{1}{2} C_0 = C_0 \\exp(-k_e t_{1/2})\n$$\n$$\n\\frac{1}{2} = \\exp(-k_e t_{1/2})\n$$\nTaking the natural logarithm of both sides gives:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = -k_e t_{1/2}\n$$\n$$\n-\\ln(2) = -k_e t_{1/2}\n$$\nThis establishes the relationship between the elimination rate constant $k_e$ and the half-life $t_{1/2}$:\n$$\nk_e = \\frac{\\ln(2)}{t_{1/2}}\n$$\nDuring continuous administration with a constant dosing rate (as approximated by multiple dosing), the drug concentration accumulates and approaches an asymptotic steady-state concentration, $C_{ss}$. The kinetics of accumulation are the inverse of the kinetics of elimination. The fraction of the steady-state concentration, $f_{ss}$, achieved at time $t$ after starting the regimen is given by:\n$$\nf_{ss}(t) = 1 - \\exp(-k_e t)\n$$\nThe problem provides a clinical convention for \"near steady state\": the time $t_{ss}$ at which the concentration has reached at least $1 - 2^{-5}$ of its asymptotic value. We set $f_{ss}(t_{ss})$ to this value:\n$$\nf_{ss}(t_{ss}) = 1 - \\exp(-k_e t_{ss}) = 1 - 2^{-5}\n$$\nFrom this equality, we can solve for $t_{ss}$:\n$$\n\\exp(-k_e t_{ss}) = 2^{-5}\n$$\nTaking the natural logarithm of both sides:\n$$\n-k_e t_{ss} = \\ln(2^{-5}) = -5 \\ln(2)\n$$\n$$\nt_{ss} = \\frac{5 \\ln(2)}{k_e}\n$$\nNow, we substitute the previously derived expression for $k_e$:\n$$\nt_{ss} = \\frac{5 \\ln(2)}{\\frac{\\ln(2)}{t_{1/2}}} = 5 t_{1/2}\n$$\nThis is the derived expression for the time to reach near steady state.\n\nNext, we use the provided data to calculate a numerical value for $t_{ss}$. The elimination half-life is given as $t_{1/2} = 21.3$ hours.\n$$\nt_{ss} = 5 \\times 21.3 \\text{ hours} = 106.5 \\text{ hours}\n$$\nThe problem requires scheduling the first serum level measurement. This measurement must be a trough level, taken just prior to a scheduled dose, and must occur at or after $t_{ss}$. The dosing interval is specified as $\\tau = 12$ hours. Trough samples can thus only be drawn at times that are integer multiples of the dosing interval, measured from the time of the first dose (at $t=0$). Let the time of the trough measurement be $T_{trough}$. The possible values for $T_{trough}$ are $n\\tau$, where $n$ is a positive integer.\n\nWe need to find the smallest integer $n$ such that $T_{trough} \\ge t_{ss}$.\n$$\nn \\tau \\ge t_{ss}\n$$\n$$\nn \\times 12 \\text{ hours} \\ge 106.5 \\text{ hours}\n$$\nSolving for $n$:\n$$\nn \\ge \\frac{106.5}{12}\n$$\n$$\nn \\ge 8.875\n$$\nSince $n$ must be an integer (representing the number of dosing intervals that have passed), the smallest integer value satisfying this condition is $n=9$.\n\nThe earliest scheduled trough time is therefore:\n$$\nT_{trough} = 9 \\times \\tau = 9 \\times 12 \\text{ hours} = 108 \\text{ hours}\n$$\nThe problem requires the answer to be rounded to four significant figures. The calculated value is exactly $108$. To express this with four significant figures, we write it as $108.0$.", "answer": "$$\n\\boxed{108.0}\n$$", "id": "4730649"}, {"introduction": "Achieving a stable, therapeutic drug level is a key milestone, but clinical vigilance is required when new medications are introduced. Co-administered drugs can alter clearance ($CL$), disrupting the steady-state equilibrium and creating risks of toxicity or treatment failure. This practice [@problem_id:4730657] models the common interaction between lithium and NSAIDs, which reduce lithium's renal clearance, demonstrating how to quantitatively predict the resulting change in concentration and calculate a proactive dose adjustment to maintain safety.", "problem": "A patient with bipolar I disorder is stabilized on immediate-release lithium carbonate at a total daily dose of $900$ mg given as $300$ mg three times daily, with a recently confirmed steady-state trough serum lithium concentration of $0.80$ mmol/L after more than $7$ days on a stable regimen. Baseline renal function is normal, and the lithium elimination half-life is estimated at $24$ hours. On day $0$, the patient begins scheduled naproxen, a Nonsteroidal Anti-Inflammatory Drug (NSAID), at anti-inflammatory doses. Assume, based on well-tested pharmacokinetic data, that naproxen reduces renal lithium clearance by a fraction of $0.25$ at steady dosing, without changing bioavailability or the apparent volume of distribution, and that lithium displays linear, one-compartment pharmacokinetics over the therapeutic range.\n\nUsing only fundamental pharmacokinetic relations, do the following:\n- Predict the direction and the fractional magnitude of change in the steady-state serum lithium concentration if the lithium dose is not adjusted immediately after naproxen initiation.\n- Calculate a provisional new total daily lithium carbonate dose needed to maintain the target trough of $0.80$ mmol/L under the new clearance, expressing the answer in mg. Round your calculated dose to three significant figures.\n- Outline a scientifically justified first-week monitoring plan that addresses timing of lithium level checks, renal function assessment, and clinical surveillance, grounded in the expected time course of approaching the new steady-state after the clearance change.\n\nExpress the final daily dose in mg, and round it to three significant figures. The final answer must be a single real-valued number.", "solution": "The user has provided a problem in clinical pharmacokinetics. I will first validate the problem's integrity and then proceed to a solution if it is deemed valid.\n\n### Step 1: Extract Givens\n-   **Patient condition:** Bipolar I disorder.\n-   **Initial drug regimen:** Immediate-release lithium carbonate.\n-   **Initial total daily dose ($D_{old}$):** $900$ mg, administered as $300$ mg three times daily.\n-   **Initial steady-state trough concentration ($C_{ss,trough,old}$):** $0.80$ mmol/L, confirmed after more than $7$ days on this dose.\n-   **Initial elimination half-life ($t_{1/2}$):** $24$ hours.\n-   **Interacting drug:** Naproxen (an NSAID), started on day $0$.\n-   **Pharmacokinetic interaction:** Naproxen reduces renal lithium clearance by a fraction of $0.25$.\n-   **Invariant parameters:** Bioavailability ($F$) and apparent volume of distribution ($V_d$) are unchanged.\n-   **Pharmacokinetic model:** Linear, one-compartment pharmacokinetics.\n-   **Tasks:**\n    1.  Predict the direction and fractional magnitude of change in steady-state serum lithium concentration.\n    2.  Calculate the new total daily lithium carbonate dose to maintain the target trough of $0.80$ mmol/L.\n    3.  Outline a first-week monitoring plan.\n-   **Final answer requirement:** The new daily dose in mg, rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established validation criteria.\n\n-   **Scientifically Grounded:** The problem describes a well-documented and clinically significant drug-drug interaction between lithium and NSAIDs. The mechanism, reduction of renal clearance, is correct. The assumption of a one-compartment linear model is a standard and appropriate simplification for lithium pharmacokinetics in many clinical contexts. The provided values for dose ($900$ mg/day), trough concentration ($0.80$ mmol/L), and half-life ($24$ hours) are all clinically plausible and internally consistent. The magnitude of clearance reduction ($25\\%$) is also within the range reported in literature. The problem is firmly based on established principles of pharmacology and pharmacokinetics.\n-   **Well-Posed:** The problem provides all necessary information to determine the requested quantities. The objectives are clearly stated, and a unique, meaningful solution can be calculated from the givens.\n-   **Objective:** The problem is stated in precise, objective, and quantitative language, free from subjectivity or bias.\n\n**Verdict:** The problem is scientifically sound, well-posed, and objective. It does not violate any of the invalidity criteria. Therefore, the problem is **valid**, and a solution will be provided.\n\n### Step 3: Proceed to Solution\n\nThis problem involves the application of fundamental pharmacokinetic principles related to steady-state drug concentrations, drug clearance, and half-life.\n\n**Part 1: Predict the change in steady-state concentration**\n\nFor a drug exhibiting linear, first-order pharmacokinetics, the average concentration at steady state ($C_{ss,avg}$) is directly proportional to the dosing rate ($R_0$) and inversely proportional to the total body clearance ($CL$). The dosing rate is the dose per unit time ($D/\\tau$).\n$$C_{ss,avg} = \\frac{F \\cdot D}{CL \\cdot \\tau} = \\frac{F \\cdot R_0}{CL}$$\nwhere $F$ is the bioavailability. In a multiple-dosing regimen, all concentrations at steady state (including peak, trough, and average) are proportional to the ratio of the dosing rate to the clearance.\n$$C_{ss} \\propto \\frac{R_0}{CL}$$\nLet $CL_{old}$ be the initial clearance and $CL_{new}$ be the clearance after the initiation of naproxen. The problem states that naproxen reduces renal lithium clearance by a fraction of $0.25$. Since lithium is almost exclusively eliminated by the kidneys (greater than $95\\%$), it is a reasonable and standard simplification in this context to assume the total body clearance is reduced by this fraction.\n$$CL_{new} = CL_{old} - (0.25 \\cdot CL_{old}) = (1 - 0.25) \\cdot CL_{old} = 0.75 \\cdot CL_{old}$$\nIf the lithium dose is not adjusted, the dosing rate ($R_0$) remains constant. We can find the ratio of the new steady-state concentration ($C_{ss,new}$) to the old one ($C_{ss,old}$).\n$$\\frac{C_{ss,new}}{C_{ss,old}} = \\frac{R_0 / CL_{new}}{R_0 / CL_{old}} = \\frac{CL_{old}}{CL_{new}}$$\nSubstituting the relationship between the new and old clearance:\n$$\\frac{C_{ss,new}}{C_{ss,old}} = \\frac{CL_{old}}{0.75 \\cdot CL_{old}} = \\frac{1}{0.75} = \\frac{4}{3} \\approx 1.333$$\nThis ratio being greater than $1$ indicates that the **direction of change is an increase**.\n\nThe fractional magnitude of change is calculated as:\n$$\\text{Fractional Change} = \\frac{C_{ss,new} - C_{ss,old}}{C_{ss,old}} = \\frac{C_{ss,new}}{C_{ss,old}} - 1$$\n$$\\text{Fractional Change} = \\frac{4}{3} - 1 = \\frac{1}{3}$$\nThus, the steady-state lithium concentration is predicted to **increase by a fractional magnitude of $1/3$** (or approximately $33.3\\%$) if the dose is not adjusted.\n\n**Part 2: Calculate the new lithium dose**\n\nThe goal is to adjust the dose to achieve a new steady state concentration equal to the original target, i.e., $C_{ss,new,target} = C_{ss,old} = 0.80$ mmol/L. Let the new dosing rate be $R_{0,new}$ and the old dosing rate be $R_{0,old}$.\nTo maintain the same steady-state concentration, the ratio of dosing rate to clearance must remain constant:\n$$\\frac{R_{0,new}}{CL_{new}} = \\frac{R_{0,old}}{CL_{old}}$$\nSolving for the new dosing rate:\n$$R_{0,new} = R_{0,old} \\cdot \\frac{CL_{new}}{CL_{old}}$$\nSince the total daily dose ($D$) is directly proportional to the dosing rate for a fixed dosing interval, we can write:\n$$D_{new} = D_{old} \\cdot \\frac{CL_{new}}{CL_{old}}$$\nWe are given $D_{old} = 900$ mg/day and we found that $CL_{new}/CL_{old} = 0.75$.\n$$D_{new} = (900 \\text{ mg/day}) \\cdot (0.75)$$\n$$D_{new} = 675 \\text{ mg/day}$$\nThe problem asks for the answer to be rounded to three significant figures. The calculated value of $675$ mg already has three significant figures.\n\n**Part 3: Outline a first-week monitoring plan**\n\nA scientifically justified monitoring plan must be based on the pharmacokinetic properties of lithium, primarily its elimination half-life ($t_{1/2}$), and the clinical risks associated with the drug interaction.\n\nThe time to reach a new steady state is determined by the elimination half-life. It takes approximately $4-5$ half-lives to reach over $94\\%$ of a new steady-state level. Given $t_{1/2} = 24$ hours, this corresponds to $4-5$ days. The most prudent clinical action is to proactively adjust the dose based on the calculation in Part 2 and then monitor to confirm the outcome.\n\nA justified first-week monitoring plan is as follows:\n-   **Day 0 (Naproxen Initiation):**\n    1.  **Dose Adjustment:** Proactively reduce the total daily lithium carbonate dose from $900$ mg to the calculated $675$ mg. This could be administered, for example, as $300$ mg in the morning and $375$ mg at night, or by other arrangements that approximate this total, depending on available formulations.\n    2.  **Patient Education:** Counsel the patient and any caregivers on the reason for the dose change and the early signs and symptoms of lithium toxicity (e.g., increased tremor, nausea, vomiting, diarrhea, muscle weakness, ataxia, confusion, slurred speech). Instruct the patient to report these symptoms immediately.\n    3.  **Documentation:** Ensure baseline renal function (serum creatinine, BUN) is documented before or on the day of naproxen initiation.\n\n-   **Days 1-4 (Approach to New Steady State):**\n    1.  **Clinical Surveillance:** Maintain close clinical contact or have the patient self-monitor for any signs of toxicity. Even with a dose reduction, individual variability exists, and toxicity is still possible.\n\n-   **Days 5-7 (New Steady-State Assessment):**\n    1.  **Trough Lithium Level:** Schedule a blood draw to measure a $12$-hour post-dose trough serum lithium level. This timing is critical because the new steady state should be reached after approximately $5$ half-lives ($5 \\times 24 \\text{ hours} = 5 \\text{ days}$). The result will verify if the new dose of $675$ mg/day successfully maintained the target concentration of approximately $0.80$ mmol/L.\n    2.  **Renal Function Monitoring:** Simultaneously measure serum creatinine and electrolytes to assess for any adverse effects of naproxen on renal function itself, which would be an independent risk factor.\n    3.  **Further Adjustment:** Based on the results of the lithium level and renal function tests, decide if further minor dose adjustments or other interventions are necessary.\n\nThis plan integrates pharmacokinetic predictions with essential clinical safety measures, addressing the specific risks posed by the drug interaction over the time course in which they are expected to evolve.", "answer": "$$\\boxed{675}$$", "id": "4730657"}, {"introduction": "Standard laboratory assays report a drug's *total* concentration, but it is the *free*, or unbound, fraction that is pharmacologically active. For a highly protein-bound drug like valproic acid, physiological states such as hypoalbuminemia can dramatically increase the free concentration even when the total level appears normal. This advanced exercise [@problem_id:4730700] uses the principles of chemical equilibrium to calculate the active free drug concentration, revealing how a seemingly therapeutic total level can mask a true risk of toxicity.", "problem": "A patient with bipolar disorder is maintained on valproic acid and presents with hypoalbuminemia. Only the pharmacologically active, unbound drug fraction contributes to central nervous system effects and toxicity, so dose decisions should be based on the free concentration rather than the total concentration when protein binding is altered. Consider valproic acid binding to human serum albumin as a reversible, single-site interaction governed by the law of mass action. Let the drug dissociation constant be $K_{d}$, the total albumin concentration be $A_{\\text{tot}}$, the binding stoichiometry be $n$ sites per albumin molecule, the total valproic acid concentration be $D_{\\text{tot}}$, and the free (unbound) valproic acid concentration be $D_{\\text{free}}$. The bound drug concentration arises from site occupancy on albumin according to equilibrium thermodynamics. The fraction unbound ($f_{u}$) is defined as $f_{u} = D_{\\text{free}}/D_{\\text{tot}}$, and the clinical free target range for valproate is $5$ to $15$ $\\text{mg/L}$.\n\nUse the following scientifically plausible parameters:\n- Serum albumin $= 2.8$ $\\text{g/dL}$.\n- Total valproic acid $= 70$ $\\text{mg/L}$.\n- Valproic acid molecular weight $= 144.21$ $\\text{g/mol}$.\n- Human serum albumin molecular weight $= 66{,}500$ $\\text{g/mol}$.\n- Single high-affinity site ($n = 1$) with dissociation constant $K_{d} = 50$ $\\mu\\text{mol/L}$.\n\nStarting from the reversible binding equilibrium and mass conservation, derive the expression for $D_{\\text{free}}$ and compute the free valproic acid concentration. Express $D_{\\text{free}}$ in $\\text{mg/L}$. Then define the decision indicator $\\delta$ such that $\\delta = 1$ if $D_{\\text{free}}$ exceeds $15$ $\\text{mg/L}$ (indicating that a dose reduction should be considered despite a “normal” total level), and $\\delta = 0$ otherwise. Round $D_{\\text{free}}$ to four significant figures. Report your final answer as the ordered pair $\\left(D_{\\text{free}}, \\delta\\right)$.", "solution": "The problem requires the derivation and calculation of the free (unbound) concentration of valproic acid given a set of clinical and biochemical parameters. The core of the problem lies in the application of the law of mass action to a reversible drug-protein binding equilibrium.\n\nWe begin by defining the equilibrium for the binding of the drug ($D$) to albumin ($A$), which is stated to be a single-site interaction ($n=1$):\n$$ D + A \\rightleftharpoons DA $$\nHere, $D$ represents the free drug, $A$ represents the free albumin, and $DA$ represents the drug-albumin complex. The dissociation constant, $K_d$, governs this equilibrium:\n$$ K_d = \\frac{[D_{\\text{free}}][A_{\\text{free}}]}{[DA]} $$\nThe square brackets denote molar concentrations. $[D_{\\text{free}}]$ is the concentration of free drug, $[A_{\\text{free}}]$ is the concentration of free albumin, and $[DA]$ is the concentration of the bound complex.\n\nThe total concentrations of the drug, $[D_{\\text{tot}}]$, and albumin, $[A_{\\text{tot}}]$, are conserved. The mass balance equations are:\n$$ [D_{\\text{tot}}] = [D_{\\text{free}}] + [DA] \\quad (1) $$\n$$ [A_{\\text{tot}}] = [A_{\\text{free}}] + [DA] \\quad (2) $$\n\nOur goal is to find an expression for $[D_{\\text{free}}]$. We can express the unknown concentrations $[DA]$ and $[A_{\\text{free}}]$ in terms of $[D_{\\text{free}}]$, $[D_{\\text{tot}}]$, and $[A_{\\text{tot}}]$.\nFrom equation (1), we rearrange to find $[DA]$:\n$$ [DA] = [D_{\\text{tot}}] - [D_{\\text{free}}] \\quad (3) $$\nSubstituting this into equation (2) allows us to find $[A_{\\text{free}}]$:\n$$ [A_{\\text{free}}] = [A_{\\text{tot}}] - [DA] = [A_{\\text{tot}}] - ([D_{\\text{tot}}] - [D_{\\text{free}}]) \\quad (4) $$\nNow, we substitute expressions (3) and (4) into the equilibrium equation for $K_d$:\n$$ K_d = \\frac{[D_{\\text{free}}] \\left( [A_{\\text{tot}}] - [D_{\\text{tot}}] + [D_{\\text{free}}] \\right)}{[D_{\\text{tot}}] - [D_{\\text{free}}]} $$\nTo solve for $[D_{\\text{free}}]$, we rearrange this equation into a quadratic form. Let $x = [D_{\\text{free}}]$ for simplicity:\n$$ K_d([D_{\\text{tot}}] - x) = x([A_{\\text{tot}}] - [D_{\\text{tot}}] + x) $$\n$$ K_d[D_{\\text{tot}}] - K_d x = x[A_{\\text{tot}}] - x[D_{\\text{tot}}] + x^2 $$\nArranging into the standard form $ax^2 + bx + c = 0$:\n$$ x^2 + ([A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d)x - K_d[D_{\\text{tot}}] = 0 $$\nThis is the derived expression. We solve for $x$ (which is $[D_{\\text{free}}]$) using the quadratic formula:\n$$ [D_{\\text{free}}] = \\frac{-([A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d) \\pm \\sqrt{([A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d)^2 - 4(1)(-K_d[D_{\\text{tot}}])}}{2} $$\nSince a concentration must be a positive physical quantity, and the term under the square root is strictly positive and larger than the squared term outside it, we must select the positive root:\n$$ [D_{\\text{free}}] = \\frac{-([A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d) + \\sqrt{([A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d)^2 + 4K_d[D_{\\text{tot}}]}}{2} $$\nNext, we convert the provided parameters to a consistent set of molar units, specifically $\\mu\\text{mol/L}$.\nThe dissociation constant is given as $K_d = 50$ $\\mu\\text{mol/L}$.\n\nTotal albumin concentration, $[A_{\\text{tot}}]$:\nThe mass concentration is $2.8$ $\\text{g/dL}$, which is $28$ $\\text{g/L}$. The molecular weight is $M_{W, A} = 66,500$ $\\text{g/mol}$.\n$$ [A_{\\text{tot}}] = \\frac{28 \\text{ g/L}}{66500 \\text{ g/mol}} \\approx 4.210526 \\times 10^{-4} \\text{ mol/L} = 421.0526 \\text{ } \\mu\\text{mol/L} $$\n\nTotal valproic acid concentration, $[D_{\\text{tot}}]$:\nThe mass concentration is $70$ $\\text{mg/L}$, which is $0.070$ $\\text{g/L}$. The molecular weight is $M_{W, D} = 144.21$ $\\text{g/mol}$.\n$$ [D_{\\text{tot}}] = \\frac{0.070 \\text{ g/L}}{144.21 \\text{ g/mol}} \\approx 4.854032 \\times 10^{-4} \\text{ mol/L} = 485.4032 \\text{ } \\mu\\text{mol/L} $$\n\nWe now substitute these molar concentrations into the quadratic equation solution. Let all concentrations be in $\\mu\\text{mol/L}$.\nThe coefficient $b$ of the quadratic equation is:\n$$ b = [A_{\\text{tot}}] - [D_{\\text{tot}}] + K_d = 421.0526 - 485.4032 + 50 = -14.3506 $$\nThe solution for $[D_{\\text{free}}]$ in $\\mu\\text{mol/L}$ is:\n$$ [D_{\\text{free}}] = \\frac{-(-14.3506) + \\sqrt{(-14.3506)^2 + 4(50)(485.4032)}}{2} $$\n$$ [D_{\\text{free}}] = \\frac{14.3506 + \\sqrt{205.9397 + 97080.64}}{2} $$\n$$ [D_{\\text{free}}] = \\frac{14.3506 + \\sqrt{97286.5797}}{2} $$\n$$ [D_{\\text{free}}] = \\frac{14.3506 + 311.90796}{2} = \\frac{326.25856}{2} = 163.12928 \\text{ } \\mu\\text{mol/L} $$\n\nThe problem requires the answer for free drug concentration, $D_{\\text{free}}$, in $\\text{mg/L}$. We convert the molar concentration back to a mass concentration:\n$$ D_{\\text{free}} (\\text{in mg/L}) = [D_{\\text{free}}] (\\text{in mol/L}) \\times M_{W, D} (\\text{in g/mol}) \\times 1000 \\text{ mg/g} $$\n$$ D_{\\text{free}} = (163.12928 \\times 10^{-6} \\text{ mol/L}) \\times (144.21 \\text{ g/mol}) \\times 1000 \\text{ mg/g} $$\n$$ D_{\\text{free}} \\approx 23.5269 \\text{ mg/L} $$\nRounding to four significant figures as requested, we obtain:\n$$ D_{\\text{free}} = 23.53 \\text{ mg/L} $$\n\nFinally, we determine the decision indicator $\\delta$. The criterion is $\\delta = 1$ if $D_{\\text{free}}  15 \\text{ mg/L}$ and $\\delta = 0$ otherwise. Since our calculated value $D_{\\text{free}} = 23.53 \\text{ mg/L}$ is greater than the threshold of $15 \\text{ mg/L}$, the indicator is:\n$$ \\delta = 1 $$\n\nThe final answer is the ordered pair $(D_{\\text{free}}, \\delta)$.", "answer": "$$\n\\boxed{(23.53, 1)}\n$$", "id": "4730700"}]}